Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EPS (Weighted Average and Diluted) (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.32 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 89.08% year-over-year to -$0.32, compared with a TTM value of $3.44 through Sep 2025, up 104.6%, and an annual FY2024 reading of -$11.41, up 82.5% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.32 for Q3 2025 at Atara Biotherapeutics, down from -$0.01 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.5 in Q1 2025 and bottomed at -$63.14 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$6.09, with a median of -$0.73 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 8549.32% in 2023, then skyrocketed 161.95% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.73 in 2022, then tumbled by 8549.32% to -$63.14 in 2023, then skyrocketed by 100.43% to $0.27 in 2024, then crashed by 218.52% to -$0.32 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ATRA at -$0.32 in Q3 2025, -$0.01 in Q2 2025, and $3.5 in Q1 2025.